Biogen to Pay Elan $3.25 Billion for Full Tysabri Rights

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

Biogen to Pay Elan $3.25 Billion for Full Tysabri Rights

Postby MSUK » Wed Feb 06, 2013 2:45 am

Biogen Idec Inc. agreed to acquire partner Elan Corp.’s stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties.

The deal gives Biogen all rights to the product, and the company will pay royalties to Elan, Dublin-based Elan said in a statement today. The companies had been splitting profit equally on the medicine, which generated $1.6 billion in sales in 2012.

The deal ends speculation that Biogen would buy Elan and transforms the Irish company into an investment vehicle in search of assets to buy in health care. Elan’s experimental drug for Alzheimer’s disease failed in late-stage trials last year, leaving Tysabri as the company’s single major product..... Read More - http://www.ms-uk.org/index.cfm/tysabri
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2180
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Re: Biogen to Pay Elan $3.25 Billion for Full Tysabri Rights

Postby HarryZ » Thu Feb 07, 2013 3:36 pm

Wonder if Elan has decided to grab the big profit now before Tysabri's market share starts to sink.
User avatar
HarryZ
Family Elder
 
Posts: 2557
Joined: Tue May 25, 2004 3:00 pm
Location: London, ON, Canada

Re: Biogen to Pay Elan $3.25 Billion for Full Tysabri Rights

Postby DizzyDean » Thu Feb 28, 2013 9:22 pm

Is Biogen hedging BG12? I thought BG12 was going to grab quite a bit of market share away from Tysabri...
User avatar
DizzyDean
Family Member
 
Posts: 45
Joined: Fri Jun 01, 2007 3:00 pm

Re: Biogen to Pay Elan $3.25 Billion for Full Tysabri Rights

Postby HarryZ » Fri Mar 01, 2013 8:11 am

DizzyDean wrote:Is Biogen hedging BG12? I thought BG12 was going to grab quite a bit of market share away from Tysabri...


It wouldn't take much to take market share away from Tysabri due to its ongoing problems with severe side effects.

Biogen is banking on BG12 to be a blockbuster product or at least close to one. That means replacing the revenue that Tysabri is generating at the moment. It's all about market share and combining these two markets would indeed bring Biogen a lot of revenue.

Although Biogen tells us that BG12 is safe, the drug hasn't been used long enough with MS patients to really give us a solid data base. Remember it was Biogen who initially told us that Tysabri was very safe!

Harry
User avatar
HarryZ
Family Elder
 
Posts: 2557
Joined: Tue May 25, 2004 3:00 pm
Location: London, ON, Canada


Return to Tysabri (Antegren or Natalizumab)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service